JY
DYN icon

Jeff Yass’s Dyne Therapeutics DYN Stock Holding History

Jeff Yass’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Buy
14,900
+1,100
+8% +$20.5K ﹤0.01% 10824
2026
Q1 		$250K Sell
13,800
-94,300
-87% -$1.63M ﹤0.01% 11266
2025
Q4 		$2.11M Buy
108,100
+97,400
+910% +$1.84M ﹤0.01% 5546
2025
Q3 		$135K Buy
+10,700
New +$122K ﹤0.01% 11362
2025
Q2 		– Sell
-41,900
Closed -$438K – 12860
2025
Q1 		$438K Sell
41,900
-19,400
-32% -$278K ﹤0.01% 9188
2024
Q4 		$1.44M Sell
61,300
-103,600
-63% -$3.06M ﹤0.01% 6040
2024
Q3 		$5.92M Buy
164,900
+140,600
+579% +$5.6M ﹤0.01% 3324
2024
Q2 		$858K Sell
24,300
-13,000
-35% -$378K ﹤0.01% 6942
2024
Q1 		$1.06M Buy
37,300
+15,800
+73% +$357K ﹤0.01% 6754
2023
Q4 		$286K Buy
+21,500
New +$210K ﹤0.01% 9937

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jeff Yass's DYN Position: Q2 2026 in Review

Jeff Yass reduced its Dyne Therapeutics (DYN) stake by 57% in Q2 2026, selling an estimated $1.15M and leaving 47,127 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #8087.

Jeff Yass first reported a position in DYN in Q1 2021 and has held it in 17 quarters since. The position peaked at $12.5M in Q1 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Jeff Yass held 47,127 shares of Dyne Therapeutics worth $1.05M as of Q2 2026.
  • Jeff Yass sold 61,597 Dyne Therapeutics shares in Q2 2026, an estimated $1.15M.
  • Dyne Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8087 holding.
  • Jeff Yass first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 17 quarters since.
  • Jeff Yass's Dyne Therapeutics position peaked at $12.5M in Q1 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.